TW322478B - - Google Patents

Download PDF

Info

Publication number
TW322478B
TW322478B TW084101083A TW84101083A TW322478B TW 322478 B TW322478 B TW 322478B TW 084101083 A TW084101083 A TW 084101083A TW 84101083 A TW84101083 A TW 84101083A TW 322478 B TW322478 B TW 322478B
Authority
TW
Taiwan
Prior art keywords
group
ministry
page
ring
cns
Prior art date
Application number
TW084101083A
Other languages
English (en)
Chinese (zh)
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Application granted granted Critical
Publication of TW322478B publication Critical patent/TW322478B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW084101083A 1994-02-10 1995-02-09 TW322478B (OSRAM)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP1682994 1994-02-10
JP3506494 1994-03-04
JP10257994 1994-05-17
JP22133594 1994-09-16
JP26741294 1994-10-31

Publications (1)

Publication Number Publication Date
TW322478B true TW322478B (OSRAM) 1997-12-11

Family

ID=27519861

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084101083A TW322478B (OSRAM) 1994-02-10 1995-02-09

Country Status (7)

Country Link
EP (1) EP0747355A4 (OSRAM)
KR (1) KR970701174A (OSRAM)
AU (1) AU685225B2 (OSRAM)
CA (1) CA2182568A1 (OSRAM)
HU (1) HUT76289A (OSRAM)
TW (1) TW322478B (OSRAM)
WO (1) WO1995021820A1 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739869D1 (de) * 1996-03-20 2010-06-17 Univ Wake Forest Health Sciences Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
WO1998054167A1 (en) * 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Indole compounds
HUP0102404A2 (hu) * 1998-02-04 2001-11-28 Banyu Pharmaceutical Co., Ltd. N-acilezett gyűrűs aminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1213281B1 (en) 1999-07-23 2004-02-18 Banyu Pharmaceutical Co., Ltd. Novel amide derivatives
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
ATE299494T1 (de) 1999-12-07 2005-07-15 Theravance Inc Carbamat-derivate als muscarin-rezeptor antonisten
ATE256682T1 (de) 2000-04-27 2004-01-15 Univ Wake Forest Health Sciences Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
PL201530B1 (pl) * 2000-06-27 2009-04-30 L V A T Lab Sa Karbaminiany pochodne aryloalkiloamin i zastosowanie karbaminianów pochodnych aryloalkiloamin
WO2002051841A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
BR0116624A (pt) 2000-12-28 2003-12-23 Almirall Prodesfarma Ag Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação
CA2464660C (en) * 2001-10-26 2011-12-20 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
BR0215348A (pt) * 2001-12-20 2004-11-16 S A L V A T Lab Sa Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico
SI1466912T1 (sl) 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
DE10255040A1 (de) * 2002-11-26 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbaminsäureester mit anticholinerger Wirksamkeit
US7041674B2 (en) * 2002-11-26 2006-05-09 Boehringer Ingelhiem Pharma Gmbh & Co. Kg Carbamic acid esters with anticholinergic activity
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2005051946A2 (en) 2003-11-21 2005-06-09 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200534855A (en) * 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2007528415A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723113A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528408A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2007528416A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1866284A1 (en) 2005-03-10 2007-12-19 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008533028A (ja) 2005-03-10 2008-08-21 セラヴァンス, インコーポレーテッド ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7479562B2 (en) * 2005-03-10 2009-01-20 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1893577A1 (en) 2005-06-13 2008-03-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1904446A2 (en) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US7973055B2 (en) 2006-03-09 2011-07-05 Theravance, Inc. Crystalline forms of a biphenyl compound
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US20100144801A1 (en) * 2006-10-03 2010-06-10 Naresh Kumar Muscarinic receptor antagonists
JP5293192B2 (ja) * 2007-02-09 2013-09-18 アステラス製薬株式会社 アザ架橋環化合物
ATE509931T1 (de) * 2007-03-23 2011-06-15 Abbott Lab Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
HRP20151344T1 (hr) 2009-07-15 2016-01-01 Theravance Biopharma R&D Ip, Llc Kristalni oblik slobodne baze bifenilnog spoja
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
KR20130141534A (ko) * 2010-11-26 2013-12-26 키에시 파르마슈티시 엣스. 피. 에이. 글리신 유도체 및 무스카린 수용체 길항제로서의 이들의 용도
TWI634119B (zh) 2011-03-18 2018-09-01 美商健臻公司 葡萄糖神經醯胺合成酶抑制劑
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
SG10201706575UA (en) * 2013-03-15 2017-09-28 Genzyme Corp Method of preparing glucosylceramide synthase inhibitors
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
WO2017114377A1 (zh) * 2015-12-29 2017-07-06 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途
MY200068A (en) 2016-08-26 2023-12-06 Dong A St Co Ltd Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof
KR102239776B1 (ko) * 2016-08-26 2021-04-13 동아에스티 주식회사 (r)-(1-메틸피롤리딘-3-일)메틸(3'-클로로-4'-플루오로-[1,1'-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형
EP3710483A4 (en) 2017-11-16 2021-10-20 XL-protein GmbH PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY
US20200308168A1 (en) * 2017-12-04 2020-10-01 Friedrich-Alexander-Universität Erlangen-Nürnberg Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2
WO2021156769A1 (en) 2020-02-03 2021-08-12 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.
CN115850157A (zh) * 2022-11-30 2023-03-28 济南大学 一种1-苄基哌啶-4-基[1,1'-联苯]-2-基氨基甲酸酯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2133083A1 (en) * 1992-03-31 1993-10-14 Alexander W. Oxford Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht antagonists

Also Published As

Publication number Publication date
HU9602188D0 (en) 1996-10-28
AU1590995A (en) 1995-08-29
WO1995021820A1 (en) 1995-08-17
HUT76289A (en) 1997-07-28
KR970701174A (ko) 1997-03-17
EP0747355A4 (en) 1997-04-09
AU685225B2 (en) 1998-01-15
EP0747355A1 (en) 1996-12-11
CA2182568A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
TW322478B (OSRAM)
JP4485353B2 (ja) 有効な抗ヒスタミン剤および抗アレルギー剤としての新規インドリルピペリジン誘導体
CA2568608C (en) Six membered amino-amide derivatives as angiogenesis inhibitors
TWI299730B (en) Piperidine derivatives,processes for their preparation ,pharmaceutical composition containing them and their medical use
TW531537B (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
TW323279B (OSRAM)
MX2011012712A (es) Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
CA2234166A1 (en) N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
TW201004941A (en) Alpha7 nicotinic acetylcholine receptor inhibitors
RS60803B1 (sr) Procesni uložak i aparat za izradu slika
TW200418857A (en) Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
US9453027B2 (en) Deuterium-enriched pyridinonecarboxamides and derivatives
KR20010021957A (ko) 피페라진 유도체
PT91287B (pt) Processo de preparacao de derivados do acido indazol-3-carboxilico e de composicoes farmaceuticas que os contem
JPH05230059A (ja) ベンゾジオキサン誘導体
JP2008525524A (ja) アリールスルホンアミドモジュレーター
TWI606043B (zh) 新穎之1位經取代吲唑衍生物
TW201920135A (zh) 吡唑衍生化合物及其用途
US20070179172A1 (en) Positive modulators of nicotinic acetylcholine receptors
JP2008524213A (ja) 新規なピラゾール誘導体及びニコチン性アセチルコリン受容体のモジュレーターとしてのそれらの使用
JP6498672B2 (ja) 疼痛に対して多重モードの活性を有するピペリジン化合物
TW421649B (en) 4-(1H-indol-1yl)-1-piperidinyl derivatives
ES2373617T3 (es) Compuestos de quinolina adecuados para tratar trastornos que responden a la modulación del receptor 5-ht6 de serotonina.
TWI236469B (en) Diamine compound with condensed-ring groups
SI9300191A (sl) Novi amidoalkil- in imidoalkil-piperazini